{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:27:17Z","timestamp":1791120437898,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.revmed.2012.05.005","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T17:48:12Z","timestamp":1353952092000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Les ch\u00e9lateurs du fer\u00a0: quand et comment les utiliser chez l\u2019adulte\u00a0?"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Ruivard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2012.05.005_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-8794-2-2","article-title":"Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases","volume":"2","author":"Kell","year":"2009","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.revmed.2012.05.005_bib0010","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1157121","article-title":"The serine protease TMPRSS6\u00a0is required to sense iron deficiency","volume":"320","author":"Du","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.revmed.2012.05.005_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1445-5994.2011.02527.x","article-title":"Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias","volume":"41","author":"Ho","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.revmed.2012.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.05.005_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2010.09.003","article-title":"Controversies surrounding iron chelation therapy for MDS","volume":"25","author":"Leitch","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.revmed.2012.05.005_bib0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/bmt.2008.99","article-title":"Iron overload in hematopoietic cell transplantation","volume":"41","author":"Majhail","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.revmed.2012.05.005_bib0035","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","article-title":"Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116\u00a0patients from the EPIC trial","volume":"116","author":"Lee","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/hep.23879","article-title":"A phase 1\/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis","volume":"52","author":"Phatak","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2012.05.005_bib0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2006-04-016949","article-title":"Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)","volume":"109","author":"Fabio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0050","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.05.005_bib0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0140-6736(04)15436-6","article-title":"Non-invasive assessment of hepatic iron stores by MRI","volume":"363","author":"Gandon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2012.05.005_bib0065","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2012.05.005_bib0070","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.V97.3.792","article-title":"Desferrioxamine-chelatable iron, a component of serum non-transferrin bound iron, used for assessing chelation therapy","volume":"97","author":"Breuer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0075","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2003-03-0807","article-title":"Labile plasma iron in iron overload: redox activity and susceptibility to chelation","volume":"102","author":"Esposito","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0080","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2004-02-0630","article-title":"Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia\/HbE patients treated with an oral chelator","volume":"104","author":"Pootrakul","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0085","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia","volume":"95","author":"Davis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0090","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2012.05.005_bib0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2012.05.005_bib0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mlc.2001.116487","article-title":"Exploring the \u201ciron shuttle\u201d hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture","volume":"138","author":"Link","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.revmed.2012.05.005_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2012.05.005_bib0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2011.08769.x","article-title":"Chelation treatment in sickle cell-anaemia: much ado about nothing?","volume":"154","author":"Lucania","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2012.05.005_bib0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","article-title":"Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging","volume":"96","author":"Pepe","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2012.05.005_bib0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2012.05.005_bib0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1749-6632.2010.05586.x","article-title":"Deferiprone","volume":"1202","author":"Piga","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.revmed.2012.05.005_bib0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14740338.2010.510831","article-title":"The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study","volume":"9","author":"Ricchi","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.revmed.2012.05.005_bib0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2010.031468","article-title":"Continued improvement in myocardial T2* over 2years of deferasirox therapy in \u03b2-thalassemia major patients with cardiac iron overload","volume":"96","author":"Borgna-Pignatti","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2012.05.005_bib0140","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0268-960X(08)70007-9","article-title":"Long-term efficacy and safety of deferasirox","volume":"22","author":"Cappellini","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.revmed.2012.05.005_bib0145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","article-title":"Long-term safety and efficacy of deferasirox (Exjade\u00ae) for up to 5years in transfusional iron-overloaded patients with sickle cell disease","volume":"154","author":"Vichinsky","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2012.05.005_bib0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years\u2019 follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0215","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0609.2011.01726.x","article-title":"Deferasirox treatment of iron-overloaded chelation-na\u00efve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange","volume":"88","author":"Gattermann","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2012.05.005_bib0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03630269.2011.578515","article-title":"Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome","volume":"35","author":"Cermak","year":"2011","journal-title":"Hemoglobin"},{"key":"10.1016\/j.revmed.2012.05.005_bib0165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2009-11-250308","article-title":"The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores","volume":"116","author":"Wood","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0170","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"Darbari","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2012.05.005_bib0180","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1182\/blood-2008-09-038935","article-title":"How I treat patients with myelodysplastic syndromes?","volume":"113","author":"Stone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.20091488","article-title":"Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia","volume":"207","author":"Callens","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2012.05.005_bib0195","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","article-title":"Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des My\u00e9lodysplasies)","volume":"34","author":"Rose","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2012.05.005_bib0200","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2007.06666.x","article-title":"Light and shadows in the iron chelation treatment of haematological diseases","volume":"138","author":"Maggio","year":"2007","journal-title":"BJH"},{"key":"10.1016\/j.revmed.2012.05.005_bib0220","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2011-04-344507","article-title":"Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort","volume":"119","author":"Kwiatkowski","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2012.05.005_bib0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cbi.2011.12.003","article-title":"Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1\u00a0in hepatocyte cultures","volume":"195","author":"Lescoat","year":"2012","journal-title":"Chem Biol Interact"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866312005218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866312005218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:30:20Z","timestamp":1759336220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866312005218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0248866312005218"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2012.05.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les ch\u00e9lateurs du fer\u00a0: quand et comment les utiliser chez l\u2019adulte\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2012.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}